PM
SPRY icon

Prosight Management’s ARS Pharmaceuticals SPRY Stock Holding History

Prosight Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-196,257
Closed -$1.04M – 53
2022
Q3 		$1.04M Sell
196,257
-144,851
-42% -$714K 0.56% 34
2022
Q2 		$1.45M Buy
341,108
+15,743
+5% +$54.9K 1.14% 19
2022
Q1 		$1.14M Buy
325,365
+271,550
+505% +$1.18M 0.74% 25
2021
Q4 		$358K Buy
+53,815
New +$437K 0.21% 36

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management's SPRY Position: Q4 2022 in Review

Prosight Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2022, closing a stake of 196,257 shares — an estimated $1.04M sold.

Prosight Management first reported a position in SPRY in Q4 2021 and held it in 4 quarters. The position peaked at $1.45M in Q2 2022. 73 funds tracked by Wall St. Rank hold SPRY as of Q4 2022.

  • Prosight Management reported no remaining ARS Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Prosight Management sold 196,257 ARS Pharmaceuticals shares in Q4 2022, an estimated $1.04M.
  • Prosight Management first reported a position in ARS Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Prosight Management's ARS Pharmaceuticals position peaked at $1.45M in Q2 2022.
  • 73 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2022.

Based on Prosight Management's 13F filing for Q4 2022, filed 14 Feb 2023.